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Identity 
Inheritance: 'autosomal dominant' disorder with high 
penetrance (increasing with age: 97% by age 60 yrs) 
but variable expressivity (with phenotype/genotype 
correlations); frequency is about 2.5/105. 
Clinics 
The Von Hippel-Lindau (VHL) disease is a multi 
system disease predisposing to a variety of benign and 
malignant tumours, often with multifocal and/or 
bilateral localization. 
Phenotype and clinics 
Onset of the disease between 18 and 30 yrs, often with 
retinal or cerebellar hemangioblastomas. 
There are two clinical types of VHL: type I, without 
pheochromocytoma, and type II with 
pheochromocytoma; in the subtype 2A, there are no 
renal nore pancreatic lesions; the subtype 2B is the full 
multi-tissues subtype. 
Neoplastic risk 
Central nervous system hemangioblastomas are the 
most frequent lesion (infratentorial localization in 60 % 
of cases, and intraspinal in 30-40 %); 
hemangioblastomas are benign vascular proliferations. 
Retinal hemangioblastomas are quasi pathognomonic; 
most often multifocal and bilateral; peripheral 
localization preferentially. 
Renal cell carcinomas of the clear cell type, multifocal 
and bilateral; mutiple cysts and intermediate tumours 
are also found. 
Pheochromocytomas (bilateral); found in a subset of 
families, where it is often the only sign. 
Pancreas tumours: multiple cysts, mainly; islet cell 
tumours, rare. 
Endolymphatic sac tumours (adenocarcinomas) of the 
petrus bone. 
Treatment 
Screening and regular follow up are essential; 
treatments: surgery for central nervous system 
hemangioblastomas and for renal carcinomas; laser 
treatment of retinal hemangioblastoma; treatment of 
pheochromocytomas are according their symptomatic 
consequences. 
Prognosis 
According to the severity of the disease in a given 
patient, and to the quality of a regular follow up; mean 
age at death: 50 yrs; a presymptomatic diagnosis may 
improve survival data; renal manifestations have 
become the first cause of death. 
Genes involved and Proteins 
VHL 
Location: 3p25-26 
DNA / RNA 
Description: 3 exons; recessive mode of inheritance, 
although the disease appears as pseudo dominant, as is 
found with the RB1 gene: this is the result of the 
combination of a rare probability (2nd mutation) in a 
large cell population (e X 1/e = 1). 
Protein 
Description: 284 amino acids. 
Function: Tumour suppressor; down-regulate 
transcriptional elongation by binding to components of 
the elongin complex. 
Mutations 
Germinal: More than 250 mutations have been 
reported, comprising for more than 100 independant 
intragenetic mutational events; 70 % of the mutations 
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are detectable; when a patient is diagnosed, all at-risk 
relatives must be tested for the mutation; this reduc s 
significantly the mortality and morbidity; 
phenotype/genotype correlations: large deletions, 
frameshifts and nonsense mutations are often found in 
cases without pheochromocytoma, while missence 
mutations are associated with a high susceptibility to 
pheochromocytoma, which indicates that VHL 
functions may be tissue-specific. 
Somatic: Mutation and allele loss events in VHL, and 
somatic mutations, frequent in sporadic renal cell 
carcinomas and hemangioblastomas, are in accordance 
with the two-hit model for neoplasia, as is found in 
retinoblastoma; however, somatic mutations of VHL 
are rare in sporadic pheochromocytomas; gene 
methylation, an epigenetic event, can also occur in 
tumours. 
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